Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

被引：0
|
作者：
Viale, G [1 ]
Regan, M [1 ]
Dell'Orto, P [1 ]
Del Curto, B [1 ]
Braye, S [1 ]
Orosz, Z [1 ]
Brown, R [1 ]
Olszewski, WP [1 ]
Knox, F [1 ]
Oehlschlegel, C [1 ]
Thürlimann, B [1 ]
机构：
[1] BIG 1 98 Collaborat Int Breast Canc Study Grp, Bern, Switzerland
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S13 / S14
页数：2
相关论文
共 50 条
  • [31] Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen:: Safety analysis of BIG 1-98 trial
    Mouridsen, Henning
    Keshaviah, Aparna
    Coates, Alan S.
    Rabaglio, Manuela
    Castiglione-Gertsch, Monica
    Sun, Zhuoxin
    Thuerlimann, Beat
    Mauriac, Louis
    Forbes, John F.
    Paridaens, Robert
    Gelber, Richard D.
    Colleoni, Marco
    Smith, Ian
    Price, Karen N.
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (36) : 5715 - 5722
  • [32] Letrozole is cost-effective versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: BIG-1-98
    Karnon, J.
    Johnston, S. R. D.
    Delea, T.
    Barghout, V.
    Thomas, S.
    Papo, N. L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 96 - 96
  • [33] Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer
    Pan, Kathy
    Chlebowski, Rowan T.
    CLINICAL BREAST CANCER, 2014, 14 (03) : 147 - 153
  • [34] Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up
    Regan, Meredith M.
    Neven, Patrick
    Giobbie-Hurder, Anita
    Goldhirsch, Aron
    Ejlertsen, Bent
    Mauriac, Louis
    Forbes, John F.
    Smith, Ian
    Lang, Istvan
    Wardley, Andrew
    Rabaglio, Manuela
    Price, Karen N.
    Gelber, Richard D.
    Coates, Alan S.
    Thuerlimann, Beat
    LANCET ONCOLOGY, 2011, 12 (12): : 1101 - 1108
  • [35] Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1-98
    Coates, A. S.
    Mouridsen, H.
    Sun, Z.
    Rabaglio, M.
    Castiglione-Gertsch, M.
    Thurlimann, B.
    Mauriac, L.
    Price, N.
    Colleoni, M.
    Smith, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
    Leyland-Jones, Brian
    Gray, Kathryn P.
    Abramovitz, Mark
    Bouzyk, Mark
    Young, Brandon
    Long, Bradley
    Kammler, Roswitha
    Dell'Orto, Patrizia
    Biasi, Maria Olivia
    Thurlimann, Beat
    Lyng, Maria B.
    Ditzel, Henrik J.
    Harvey, Vernon J.
    Neven, Patrick
    Treilleux, Isabelle
    Rasmussen, Birgitte Bruun
    Maibach, Rudolf
    Price, Karen N.
    Coates, Alan S.
    Goldhirsch, Aron
    Pagani, Olivia
    Viale, Giuseppe
    Rae, James M.
    Regan, Meredith M.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (02) : 373 - 384
  • [37] Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
    Alkner, S.
    Jensen, M. -B.
    Rasmussen, B. B.
    Bendahl, P. -O.
    Ferno, M.
    Ryden, L.
    Mouridsen, H.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) : 481 - 490
  • [38] HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer
    Love, RR
    Duc, NB
    Havighurst, TC
    Mohsin, SK
    Zhang, Q
    DeMets, DL
    Allred, DC
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) : 453 - 457
  • [39] Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
    S. Alkner
    M.-B. Jensen
    B. B. Rasmussen
    P.-O. Bendahl
    M. Fernö
    L. Rydén
    H. Mouridsen
    Breast Cancer Research and Treatment, 2017, 166 : 481 - 490
  • [40] Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 111 - 111
12345